US Broker Ratings

Altimmune, Inc. (ALT) Stock Analysis: Exploring a Potential 462.50% Upside with Analyst Confidence

Altimmune, Inc. (NASDAQ: ALT) has emerged as a compelling investment opportunity within the biotechnology sector, particularly for those interested in high-growth potential stocks in the healthcare industry. With a market..

AbCellera Biologics Inc. (ABCL): With a 173% Potential Upside, Is Now the Time to Invest?

AbCellera Biologics Inc. (NASDAQ: ABCL) is a Canadian biotechnology company making waves in the healthcare sector with its innovative approach to antibody-based medicine development. With a market capitalization of $1.02..

Tyra Biosciences, Inc. (TYRA) Stock Analysis: Biotechnology Innovator with 30% Upside Potential

Tyra Biosciences, Inc. (NASDAQ: TYRA), a clinical-stage biotechnology company focused on precision medicine, is capturing the attention of investors with its promising pipeline and significant upside potential. With a market..

KalVista Pharmaceuticals, Inc. (KALV): Investor Outlook with 81% Potential Upside

KalVista Pharmaceuticals, Inc. (KALV) represents an intriguing prospect for investors looking to capitalize on opportunities within the healthcare sector, specifically in biotechnology. With a market cap of $970.67 million and..

Myriad Genetics, Inc. (MYGN): Stock Analysis Unveils a 68.40% Potential Upside Amidst a Challenging Market

Myriad Genetics, Inc. (NASDAQ: MYGN) remains a notable player in the healthcare sector, specifically within the diagnostics and research industry. Headquartered in Salt Lake City, Utah, this American company continues..

Emergent BioSolutions Inc. (EBS) Stock Analysis: Exploring a 48.51% Potential Upside Despite Revenue Challenges

Emergent BioSolutions Inc. (NYSE: EBS), a prominent player in the healthcare sector specializing in life sciences, presents a unique opportunity for investors seeking exposure to the drug manufacturing industry. With..

AxoGen, Inc. (AXGN) Investor Outlook: Healthcare Innovator with 25.75% Upside Potential

AxoGen, Inc. (NASDAQ: AXGN), an emerging leader in the healthcare sector focused on peripheral nerve regeneration, stands out with a compelling investment narrative. Specializing in medical devices, the company has..

Collegium Pharmaceutical, Inc. (COLL) Investor Outlook: Exploring a Promising 62% Upside Potential

Collegium Pharmaceutical, Inc. (NASDAQ: COLL) stands out in the healthcare sector with its focus on developing and commercializing innovative pain management medications. As a player in the specialty and generic..

iRadimed Corporation (IRMD) Stock Analysis: Potential Upside of Over 21% Amid Strong Revenue Growth

iRadimed Corporation (NASDAQ: IRMD), a prominent player in the healthcare sector, specializes in developing MRI-compatible medical devices. With a market capitalization of $1.26 billion, this Orlando-based company has caught the..

Personalis, Inc. (PSNL) Stock Analysis: Exploring a 56% Upside Potential in the Diagnostics & Research Sector

Investors seeking opportunities in the healthcare sector may find Personalis, Inc. (NASDAQ: PSNL) an intriguing prospect, especially with its considerable upside potential. Headquartered in Fremont, California, Personalis is a key..

Taysha Gene Therapies, Inc. (TSHA) Stock Analysis: Unpacking a 161% Potential Upside

Taysha Gene Therapies, Inc. (TSHA), a promising player in the biotechnology sector, has caught the attention of investors with its significant potential upside of 161.24%. Operating within the healthcare industry,..

Treace Medical Concepts, Inc. (TMCI) Stock Analysis: Unpacking a 232% Potential Upside Opportunity

Investors keen on exploring opportunities in the healthcare sector might find Treace Medical Concepts, Inc. (NASDAQ: TMCI) an intriguing candidate, given its potential upside of 232.03%, as indicated by analyst..

Ardelyx, Inc. (ARDX) Stock Analysis: Exploring a Potential 182.95% Upside

Ardelyx, Inc. (NASDAQ: ARDX) is drawing significant investor attention in the biotechnology sector, with a remarkable potential upside of 182.95% based on current analyst ratings. As a company focused on..

Enhabit, Inc. (EHAB) Stock Analysis: A Steady Player in the Healthcare Sector with a Modest Upside

Enhabit, Inc. (EHAB), a prominent player in the healthcare sector, specifically within the medical care facilities industry, offers investors a unique opportunity to delve into the growing demand for home..

Oruka Therapeutics, Inc. (ORKA) Stock Analysis: A Rising Star in Biotechnology with 37% Potential Upside

Oruka Therapeutics, Inc. (NASDAQ: ORKA), a dynamic player in the biotechnology sector, has recently caught the attention of investors due to its promising pipeline and a significant potential upside of..

Arvinas, Inc. (ARVN) Stock Analysis: Biotechnology Innovator with 36.84% Upside Potential

Arvinas, Inc. (NASDAQ: ARVN), a trailblazer in the biotechnology sector, is capturing the attention of investors with its innovative approach to disease treatment and a promising potential upside of 36.84%...

Precigen, Inc. (PGEN) Stock Analysis: A Biotech Gem with a 144% Potential Upside

Precigen, Inc. (NASDAQ: PGEN), a promising player in the biotech industry, has emerged as a compelling investment opportunity with a striking potential upside of 144.22%. This discovery and clinical-stage biopharmaceutical..

Autolus Therapeutics plc (AUTL) Stock Analysis: Uncovering a 596.90% Potential Upside in T Cell Therapy Innovation

Autolus Therapeutics plc (NASDAQ: AUTL), a clinical-stage biopharmaceutical company based in the United Kingdom, is making waves in the biotechnology sector with its pioneering T cell therapies designed for cancer..

Dianthus Therapeutics, Inc. (DNTH) Stock Analysis: Evaluating a Potential 54.94% Upside for Biotech Investors

Dianthus Therapeutics, Inc. (NASDAQ: DNTH) is gaining traction among investors, especially within the biotechnology sector, where its innovative approach to autoimmune disease treatments is drawing substantial attention. With a market..

Fortrea Holdings Inc. (FTRE) Stock Analysis: Navigating a 50% Upside Potential in the Biotech Arena

Investors with an eye on the healthcare sector may find Fortrea Holdings Inc. (NASDAQ: FTRE) to be an intriguing prospect, especially given its significant potential upside of 50.21% based on..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds